Balance Sheet Data
Neurocrine Biosciences, Inc. (NBIX)
$97.05
+1.36 (+1.42%)
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Total Cash | 650.91 | 670.52 | 801 | 711.30 | 989.30 | 1,771.89 | 2,423.39 | 3,314.44 | 4,533.12 | 6,199.90 |
---|---|---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||||
Account Receivables | 56.24 | 126.57 | 157.10 | 185.50 | 222.97 | 304.95 | 417.08 | 570.44 | 780.18 | 1,067.05 |
Account Receivables (%) | ||||||||||
Inventories | 10.86 | 17.29 | 28 | 30.50 | 37.10 | 50.74 | 69.40 | 94.92 | 129.82 | 177.56 |
Inventories (%) | ||||||||||
Accounts Payable | 13.80 | 46.21 | 39.40 | 51.50 | 64.14 | 87.72 | 119.97 | 164.09 | 224.42 | 306.93 |
Accounts Payable (%) | ||||||||||
Capital Expenditure | -24.81 | -14.75 | -10.90 | -23.40 | -16.50 | -47.18 | -64.52 | -88.25 | -120.69 | -165.07 |
Capital Expenditure (%) |
To support growth, companies need to keep investing in capital items – including property, plants and equipment.
To calculate this net investment,we take capital expenditure (found in the company’s statement of cash flows)
and subtract non-cash depreciation (found on the income statement).
Working capital refers to the cash a company needs for day-to-day operations.
The faster a company expands, the more cash it will need.
To calculate working capital, we take current assets and subtract current liabilities.
You can find both of these on a company’s balance sheet, which is published in its quarterly and annual financial statements.